265 related articles for article (PubMed ID: 34733290)
21. Immunotherapy Approaches Beyond PD-1 Inhibition: the Future of Cellular Therapy for Head and Neck Squamous Cell Carcinoma.
Qureshi HA; Lee SM
Curr Treat Options Oncol; 2019 Mar; 20(4):31. PubMed ID: 30874960
[TBL] [Abstract][Full Text] [Related]
22. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
[TBL] [Abstract][Full Text] [Related]
23. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade.
D'Alise AM; Leoni G; Cotugno G; Troise F; Langone F; Fichera I; De Lucia M; Avalle L; Vitale R; Leuzzi A; Bignone V; Di Matteo E; Tucci FG; Poli V; Lahm A; Catanese MT; Folgori A; Colloca S; Nicosia A; Scarselli E
Nat Commun; 2019 Jun; 10(1):2688. PubMed ID: 31217437
[TBL] [Abstract][Full Text] [Related]
24. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
25. Characterization and Differentiation of the Tumor Microenvironment (TME) of Orthotopic and Subcutaneously Grown Head and Neck Squamous Cell Carcinoma (HNSCC) in Immunocompetent Mice.
Brand M; Laban S; Theodoraki MN; Doescher J; Hoffmann TK; Schuler PJ; Brunner C
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383676
[TBL] [Abstract][Full Text] [Related]
26. Fewer tumour-specific PD-1
Xu K; Fu Y; Han Y; Xia R; Xu S; Duan S; Zhang Z; Li J
Br J Cancer; 2020 Sep; 123(6):932-941. PubMed ID: 32616847
[TBL] [Abstract][Full Text] [Related]
27. Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status.
Gangkofner DS; Holzinger D; Schroeder L; Eichmüller SB; Zörnig I; Jäger D; Wichmann G; Dietz A; Broglie MA; Herold-Mende C; Dyckhoff G; Boscolo-Rizzo P; Ezic J; Marienfeld RB; Möller P; Völkel G; Kraus JM; Kestler HA; Brunner C; Schuler PJ; Wigand M; Theodoraki MN; Doescher J; Hoffmann TK; Pawlita M; Butt J; Waterboer T; Laban S
Int J Cancer; 2019 Dec; 145(12):3436-3444. PubMed ID: 31407331
[TBL] [Abstract][Full Text] [Related]
28. HPV infection related immune infiltration gene associated therapeutic strategy and clinical outcome in HNSCC.
Zeng H; Song X; Ji J; Chen L; Liao Q; Ma X
BMC Cancer; 2020 Aug; 20(1):796. PubMed ID: 32831060
[TBL] [Abstract][Full Text] [Related]
29. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
[TBL] [Abstract][Full Text] [Related]
30. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
[TBL] [Abstract][Full Text] [Related]
31. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
[No Abstract] [Full Text] [Related]
32. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
33. The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
Outh-Gauer S; Morini A; Tartour E; Lépine C; Jung AC; Badoual C
Head Neck Pathol; 2020 Jun; 14(2):330-340. PubMed ID: 32124416
[TBL] [Abstract][Full Text] [Related]
34. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
35. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
36. A digital score of tumour-associated stroma infiltrating lymphocytes predicts survival in head and neck squamous cell carcinoma.
Shaban M; Raza SEA; Hassan M; Jamshed A; Mushtaq S; Loya A; Batis N; Brooks J; Nankivell P; Sharma N; Robinson M; Mehanna H; Khurram SA; Rajpoot N
J Pathol; 2022 Feb; 256(2):174-185. PubMed ID: 34698394
[TBL] [Abstract][Full Text] [Related]
37. Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.
Lee KL; Benz SC; Hicks KC; Nguyen A; Gameiro SR; Palena C; Sanborn JZ; Su Z; Ordentlich P; Rohlin L; Lee JH; Rabizadeh S; Soon-Shiong P; Niazi K; Schlom J; Hamilton DH
Cancer Immunol Res; 2019 Aug; 7(8):1359-1370. PubMed ID: 31292145
[TBL] [Abstract][Full Text] [Related]
38. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target.
Pierini S; Tanyi JL; Simpkins F; George E; Uribe-Herranz M; Drapkin R; Burger R; Morgan MA; Facciabene A
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814714
[TBL] [Abstract][Full Text] [Related]
39. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
40. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
